

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/785,474	02/20/2001	Rudolph Tanzi	0609.418002/JAG/JUK	6844
26111 7:	590 04/28/2004		EXAMINER	
STERNE, KESSLER, GOLDSTEIN & FOX PLLC			HAYES, ROBERT CLINTON	
	100 NEW YORK AVENUE, N.W. /ASHINGTON, DC 20005		ART UNIT	PAPER NUMBER
	•		1647	
			D. 777 . 4 . 11 FD . 04/20/200	

DATE MAILED: 04/28/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/785,474	TANZI ET AL.				
Office Action Summary	Examiner	Art Unit				
	Robert C. Hayes, Ph.D.	1647				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION  - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a re - If NO period for reply is specified above, the maximum statutory perior  - Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the maili earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a reply be tirply within the statutory minimum of thirty (30) day d will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE.	nely filed  is will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 20 February 2004.						
2a) This action is <b>FINAL</b> . 2b) ☐ Th	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
<ul> <li>4)  Claim(s) 1-15 is/are pending in the application 4a) Of the above claim(s) 1-11 and 13-15 is/a</li> <li>5)  Claim(s) is/are allowed.</li> <li>6)  Claim(s) 12 is/are rejected.</li> <li>7)  Claim(s) is/are objected to.</li> <li>8)  Claim(s) 1-15 are subject to restriction and/or</li> </ul>	re withdrawn from consideration.					
Application Papers						
9) The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
Attachment(s)						
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)						
<ol> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date <u>5/21/01</u>.</li> </ol>	Paper No(s)/Mail Da ) 5) Notice of Informal Pa 6) Other:	te atent Application (PTO-152)				

Application/Control Number: 09/785,474

Art Unit: 1647

## **DETAILED ACTION**

### Election/Restriction

1. Applicant's election without traverse of Group II (claim 12), as it relates to SEQ ID NO: 30 in Paper No. 2/20/04 is acknowledged.

Claims 1-11, 13-15, as well as claims related to other SEQ ID NOs, are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made **without** traverse in Paper No. 2/20/04.

## Claim Rejections - 35 U.S.C. § 112

2. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 12 is rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The specification describes the human PS1 polypeptide of SEQ ID NO: 30, as well as how to generically produce epitope-bearing portions thereof (e.g., pgs. 25-27 of the specification). In contrast, not a single specific epitope-bearing portion is described, and importantly, the genus merely "comprising" portions of the polypeptide of SEQ ID NO: 30 is not

Application/Control Number: 09/785,474

Art Unit: 1647

described; especially as it relates to other putative species of the presention 1. In other words, no written description is provided in the specification for any different species of PS1 polypeptide molecules, nor for any additional polypeptide sequence that merely "comprise" "epitope-bearing portions" of the polypeptide of SEQ ID NO: 30. Thus, one skilled in the art cannot reasonably structurally visualized any other functional amino acid sequence, except for the single disclosed human sequence of SEQ ID NO: 30; thereby, not currently meeting the written description requirements of 35 U.S.C. 112, first paragraph. See MPEP 2163.

## Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claim 12 is rejected under 35 U.S.C. 102(e) as being anticipated by St. George-Hyslop et al. (U.S. Patent 6,210,919 B1).

St. George-Hyslop et al. teach the PS1 polypeptide of SEQ ID NO: 30, except for a substitution at position #s 264 & 315 (columns 3, 25, 30 & 157-160; as it relates to SEQ ID NO:

Application/Control Number: 09/785,474

Art Unit: 1647

134). Thus, St. George-Hyslop's polypeptide *comprises* all other "epitope-bearing portions" of SEQ ID NO: 30; thereby, anticipating claim 12e.

#### Conclusion

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Robert Hayes whose telephone number is (571) 272-0885. The examiner can normally be reached on Monday through Thursday, and alternate Fridays from 8:30 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached on (571) 272-0887. The fax phone number for this Group is (703) 872-9306.

Robert C. Hayes, Ph.D.

April 26, 2004

1600